公开(公告)号：US20210290537A1

公开(公告)日：2021-09-23

申请号：US16467458

申请日：2017-12-08

申请人： MALLINCKRODT LLC

发明人： William McGHEE ,  Rick FITCH

IPC分类号： A61K9/127 ,  A61K9/00 ,  A61K31/473 ,  A61P35/00

摘要： The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and elinafide, wherein less than 20% of the elinafide is released in vitro from the liposome within 40 hours. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and elinafide, wherein the administration of the liposomal composition has a reduced occurrence of side effects, such as for example, muscle myopathy in the patient.

公开(公告)号：US10383823B2

公开(公告)日：2019-08-20

申请号：US16030575

申请日：2018-07-09

申请人： Mallinckrodt LLC

发明人： William McGhee

IPC分类号： A61K33/24 ,  A61K9/127

摘要： The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.

公开(公告)号：US20190175505A1

公开(公告)日：2019-06-13

申请号：US16279977

申请日：2019-02-19

申请人： MALLINCKRODT LLC

发明人： Jun Yang ,  Stephen H. Wu ,  Cliff J. Herman

IPC分类号： A61K9/127 ,  A61K9/00 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/555 ,  A61K31/337 ,  A61K31/282 ,  A61K33/24 ,  A61K31/513

摘要： The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

公开(公告)号：US09993422B2

公开(公告)日：2018-06-12

申请号：US13865286

申请日：2013-04-18

申请人： Mallinckrodt LLC

发明人： Siva N. Raman ,  Jae Han Park ,  Thomas A. Diezi ,  Clifford J. Herman ,  Sunil K. Battu ,  Eric A. Burge

IPC分类号： A61K9/46 ,  A61K45/06 ,  A61K9/20 ,  A61K31/485

CPC分类号： A61K9/0007 ,  A61K9/2031 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.

公开(公告)号：US09777022B2

公开(公告)日：2017-10-03

申请号：US15061649

申请日：2016-03-04

申请人： Mallinckrodt LLC

发明人： Dennis A. Moore ,  Raghavan Rajagopalan

IPC分类号： C07F5/00 ,  C07D257/02 ,  C07D295/15

CPC分类号： C07F5/003 ,  C07D257/02 ,  C07D295/15

摘要： The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.

公开(公告)号：US20170224826A1

公开(公告)日：2017-08-10

申请号：US15417541

申请日：2017-01-27

申请人： MALLINCKRODT LLC

发明人： Brad L. Gower ,  Jae Han Park ,  Clifford J. Herman ,  Tsz Chung Lai ,  Kai Feng

IPC分类号： A61K47/36 ,  A61K31/485 ,  A61K47/34

CPC分类号： A61K31/485 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054

摘要： A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, a glucomannan, a first polyalkylene oxide having an average molecular weight of no more than 300,000, and a second polyalkylene oxide having an average molecular weight of at least 1,000,000 and methods of making. The pharmaceutical composition provides extended release of the API and has abuse deterrent features.

公开(公告)号：US20170182033A1

公开(公告)日：2017-06-29

申请号：US15457674

申请日：2017-03-13

申请人： MALLINCKRODT LLC

发明人： Krishna Devarakonda ,  Michael J. Giuliani ,  Vishal K. Gupta ,  Ralph A. Heasley ,  Susan Shelby

IPC分类号： A61K31/485 ,  A61K31/167

CPC分类号： A61K31/485 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/167 ,  A61K47/10 ,  A61K2300/00

摘要： The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subject's body faster than it is being absorbed.

公开(公告)号：US20170029432A1

公开(公告)日：2017-02-02

申请号：US15255979

申请日：2016-09-02

申请人： Mallinckrodt LLC

发明人： Bobby N. Trawick ,  David W. Berberich ,  Christopher W. Grote

IPC分类号： C07D489/08 ,  C07D489/02

CPC分类号： C07D217/20 ,  A61K31/167 ,  A61K31/472 ,  A61K31/485 ,  C07D221/28 ,  C07D489/00 ,  C07D489/02 ,  C07D489/08 ,  C07D489/10 ,  A61K2300/00

摘要： The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.

摘要翻译： 本发明提供了包含Toll样受体9（TLR9）拮抗剂活性的（+） - 吗啡喃，以及使用（+） - 吗啡来治疗疼痛的方法。 还提供了包含（+） - 吗啡喃和阿片样物质激动剂/单胺再摄取抑制剂的药物组合组合物，以及使用组合组合物治疗疼痛的方法。

公开(公告)号：US20170008832A1

公开(公告)日：2017-01-12

申请号：US15202670

申请日：2016-07-06

申请人： Mallinckrodt LLC

发明人： Doug Teramura ,  Subo Liao

IPC分类号： C07C213/02 ,  C07C45/45

CPC分类号： C07C213/02 ,  C07B2200/07 ,  C07C45/69 ,  C07C215/54 ,  C07C47/277 ,  C07C47/27

摘要： Processes for preparing 3-substituted phenylalkylamines comprising reacting a phenyl boronic compound with an α-β unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction, followed by reductive alkylation. The processes may be useful in the synthesis of tapentadol.

摘要翻译： 制备3-取代的苯基烷基胺的方法，包括通过不对称的1,4-加成反应使苯基硼化合物与含α-β-不饱和羰基的化合物反应，然后还原烷基化。 该方法可用于合成他喷他多。

公开(公告)号：US20160347747A1

公开(公告)日：2016-12-01

申请号：US15235312

申请日：2016-08-12

申请人： Mallinckrodt LLC

发明人： Peter X. Wang ,  Frank W. Moser ,  Gary L. Cantrell ,  Christopher W. Grote

IPC分类号： C07D455/03 ,  B01J31/22

CPC分类号： C07D455/03 ,  B01J31/2295 ,  B01J2231/643 ,  B01J2531/821 ,  C07D217/20

摘要： The present invention provides processes for the synthesis of substituted berbine compounds. Also provided are intermediates used in the synthesis of substituted berbine compounds.

摘要翻译： 本发明提供了合成取代的铍化合物的方法。 还提供了用于合成取代的伯贝宁化合物的中间体。